

Scientific Business Meeting Friday, 30th September 2022

Open to Working Party Members only.

09.30 – 10.30	Registration and Welcome Coffee	
10.30 – 10.45	Introduction Overview of CMWP Activity Introduction by the Local Organiser	Donal McLornan Joanna Drozd-Sokołowska Kavita Raj Francesco Onida
10.45 – 11.35	Myelodysplasia/CMML subcommittee project presentations	Marie Robin Francesco Onida Carmelo Gurnari
11.35 – 11.55	CAR-T in Plasma Cell Disorders: subcommittee plans	Nico Gagelmann Laurent Garderet
11.55 – 12.45	PH-negative Myeloproliferative Neoplasms subcommittee project presentations	Tomasz Czerw Nicola Polverelli
12.45 – 13.15	Chronic Myeloid Leukemia subcommittee project presentations	Yves Chalandon Hugues de Lavallade
13.15 – 14.15	Lunch Break	
14.15 – 14.30	Involvement of nurses in the scientific life of the CMWP	Maaïke de Ruijter
14.30 – 15.15	Plasma Cell Disorders subcommittee project presentations	Patrick Hayden Meral Beksac
15.15 – 15.45	Chronic Lymphocytic Leukemia subcommittee project presentations	Michel Van Gelder
15.45 – 16.00	An update on the EBMT registry	Johannes Schetelig
16.00 – 16.15	Closing Remarks	Donal McLornan

Educational Meeting Saturday, 1st October 2022

Open to all participants.

08.45 – 09.15	Registration and Welcome Coffee	
09.15 – 09.30	Introduction Overview of the CMWP Introduction by the Local Organiser	Donal McLornan Joanna Drozd-Sokolowska Kavita Raj Francesco Onida
	Session I: Myelodysplasia, Overlap Syndromes and VEXAS Syndrome Chairs: Kavita Raj and Joanna Drozd-Sokolowska	
09.30 – 09.50 09.50 – 10.10	Role of NGS and MRD in allo-HCT for Myelodysplasia MDS/MPN: who should we transplant? Debate: Every 'fit' VEXAS patient with a donor should be considered for allo-HCT	Marie Robin Francesco Onida Chair: Ibrahim Yakoub-Agha
10.10 – 10.25 10.25 – 10.40 10.40 – 10.55	Case for Yes Case for No Q&A	Carmelo Gurnari Raffaella Greco
	Session II: Plasma Cell Dyscrasia: CAR-T Chairs: Meral Beksac and Laurent Garderet Debate: Placement of CAR-T in the autoHCT algorithm for myeloma: the earlier the better?	
11:00 – 11.20 11.20 – 11.40 11.40 – 11.50	Case for Yes Case for No Q&A	Nico Gagelmann Patrick Hayden
11.50 – 12.20	Coffee Break	
	Session III: Myeloproliferative Neoplasms Chairs: Nicola Polverelli and Tomasz Czerw	
12.20 – 12.40 12.40 – 13.00 13.00 – 13.10	State of the Art: Optimising Haploidentical Allo-HCT in Myelofibrosis Can novel agents truly induce disease modification in Myelofibrosis? Q&A	Nicolaus Kröger Francesca Palandri
13.10 – 14.00	Lunch Break	
	Session IV: Hot Topics in CML and CLL Chairs: Yves Chalandon and Michel Van Gelder	
14.00 – 14.20 14.20 – 14.45 14.45 – 14.55	State of the Art NGS for KD mutational analysis in CML Will the advent of CAR-T for CLL completely displace allo-HCT? Q&A	Hugues de Lavallade Oliver Tournilhac
14.55 – 15.05	Conclusion	Francesco Onida Donal McLornan